← Leaderboards
Soumyajit Majumdar
University Of Mississippi
$5,403,793
Attributed
$5,625,818
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2007–24$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,973,137 · 8
By mechanism
P30$6,728,614 · 2
P20$2,006,361 · 1
R01$1,493,922 · 1
R41$355,509 · 2
R21$209,829 · 1
T32$178,902 · 1
Top collaborators
- Marie Barnard1 shared
- Mahmoud A Elsohly1 shared
- Shawnboda Deanne Mead1 shared
Most similar at University Of Mississippi
Same institution · by research overlap
- Stephen John Cutler$7,413,776
- Mahmoud A Elsohly$7,844,286
- Samir A Ross$1,721,603
- Esteban Urena-Benavides$706,374
Others in their field
Top investigators on “Mississippi”
- Robert P Kimberly · University Of Alabama At Birmingham$64,970,401
- Eric Baer · Case Western Reserve University$37,136,000
- Sandra H Harpole · Mississippi State University$36,270,963
- William J. Blot · Vanderbilt University$29,991,340
- Bruce R Korf · Harvard University (Medical School)$28,333,165
- Orlando M Gutierrez · Tufts Medical Center$24,390,643
Research focus
MississippiUniversitiesResearch Project GrantsResearch PersonnelLeadStructureProgramsNeurosciencesNeuraxisPharmacy SchoolsNatural ProductsNervous System StructureCenters Of Research ExcellenceNeuropharmacologyMentorsMemberInnovationGrantMultidisciplinaryFundingCollaborationsEnsureFacultyGenerations
Grant awards (20)
G-RISE at The University of Mississippi$178,902
T32 · FY2024 · GM
COBRE Phase III Transitional Center$1,049,220
P30 · FY2022 · GM · contact PI
Administrative Core$262,006
P30 · FY2022 · GM · contact PI
COBRE Phase III Transitional Center$1,060,594
P30 · FY2021 · GM · contact PI
Administrative Core$270,036
P30 · FY2021 · GM · contact PI
COBRE Phase III Transitional Center$1,067,817
P30 · FY2020 · GM · contact PI
Administrative Core$281,231
P30 · FY2020 · GM · contact PI
COBRE Phase III Transitional Center$1,079,288
P30 · FY2019 · GM · contact PI
Administrative Core$280,688
P30 · FY2019 · GM · contact PI
Improving treatment options and outcomes in fungal keratitis$149,995
R41 · FY2019 · EY · contact PI
COBRE Phase III Transitional Center$1,090,400
P30 · FY2018 · GM · contact PI
Evaluation and Inhibition of Efflux Pumps Expressed on the Blood Ocular Barrier$337,330
R01 · FY2018 · EY · contact PI
Administrative Core$287,334
P30 · FY2018 · GM · contact PI
Evaluation and Inhibition of Efflux Pumps Expressed on the Blood Ocular Barrier$329,060
R01 · FY2017 · EY · contact PI
Center of Research Excellence in Natural Products Neuroscience (CORE-NPN)$2,006,361
P20 · FY2016 · GM · contact PI
Evaluation and Inhibition of Efflux Pumps Expressed on the Blood Ocular Barrier$387,710
R01 · FY2016 · EY · contact PI
Evaluation and Inhibition of Efflux Pumps Expressed on the Blood Ocular Barrier$439,822
R01 · FY2015 · EY · contact PI
Orally Active Formulations of DHA Dimers for the Treatment of Infectious Diseases$205,514
R41 · FY2013 · AI
Localized modulation of RPE P-gp/MRP activity for back-of-the-eye drug delivery$103,855
R21 · FY2008 · EY · contact PI
Localized modulation of RPE P-gp/MRP activity for back-of-the-eye drug delivery$105,974
R21 · FY2007 · EY · contact PI